Trade Arrowhead Pharma - ARWR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Arrowhead Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 29.07 |
| Open* | 28.63 |
| 1-Year Change* | -2.55% |
| Day's Range* | 28.3 - 28.99 |
| 52 wk Range | 22.87-42.48 |
| Average Volume (10 days) | 1.06M |
| Average Volume (3 months) | 21.41M |
| Market Cap | 3.04B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 107.19M |
| Revenue | 256.21M |
| EPS | -1.71 |
| Dividend (Yield %) | N/A |
| Beta | 0.90 |
| Next Earnings Date | Nov 29, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 27, 2023 | 28.65 | -0.17 | -0.59% | 28.82 | 29.10 | 28.25 |
| Nov 24, 2023 | 29.07 | 0.16 | 0.55% | 28.91 | 29.58 | 28.67 |
| Nov 22, 2023 | 28.92 | 0.58 | 2.05% | 28.34 | 29.22 | 28.33 |
| Nov 21, 2023 | 28.29 | -0.12 | -0.42% | 28.41 | 28.69 | 27.95 |
| Nov 20, 2023 | 28.85 | 0.90 | 3.22% | 27.95 | 29.10 | 27.73 |
| Nov 17, 2023 | 28.01 | 1.98 | 7.61% | 26.03 | 28.21 | 26.01 |
| Nov 16, 2023 | 25.99 | -0.52 | -1.96% | 26.51 | 26.83 | 25.61 |
| Nov 15, 2023 | 26.96 | -0.40 | -1.46% | 27.36 | 28.96 | 26.91 |
| Nov 14, 2023 | 27.33 | 0.58 | 2.17% | 26.75 | 27.34 | 26.04 |
| Nov 13, 2023 | 25.92 | -0.61 | -2.30% | 26.53 | 26.57 | 25.05 |
| Nov 10, 2023 | 26.88 | -0.07 | -0.26% | 26.95 | 27.18 | 26.15 |
| Nov 9, 2023 | 26.69 | -0.51 | -1.87% | 27.20 | 27.20 | 26.51 |
| Nov 8, 2023 | 27.04 | -0.12 | -0.44% | 27.16 | 27.95 | 26.96 |
| Nov 7, 2023 | 27.44 | 0.67 | 2.50% | 26.77 | 27.52 | 26.47 |
| Nov 6, 2023 | 26.89 | -1.31 | -4.65% | 28.20 | 28.20 | 26.82 |
| Nov 3, 2023 | 28.09 | 1.57 | 5.92% | 26.52 | 28.21 | 26.52 |
| Nov 2, 2023 | 26.10 | 0.23 | 0.89% | 25.87 | 26.51 | 25.49 |
| Nov 1, 2023 | 25.73 | 0.98 | 3.96% | 24.75 | 26.31 | 24.37 |
| Oct 31, 2023 | 24.54 | 1.66 | 7.26% | 22.88 | 24.70 | 22.69 |
| Oct 30, 2023 | 23.13 | -0.47 | -1.99% | 23.60 | 24.24 | 22.87 |
Arrowhead Pharma Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, November 29, 2023 | ||
| Time (UTC) 21:00 | Country US
| Event Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Release Q4 2023 Arrowhead Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Time (UTC) 21:30 | Country US
| Event Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call Q4 2023 Arrowhead Pharmaceuticals Inc Earnings CallForecast -Previous - |
| Thursday, November 30, 2023 | ||
| Time (UTC) 18:00 | Country US
| Event Arrowhead Pharmaceuticals Inc at Piper Sandler Healthcare Conference Arrowhead Pharmaceuticals Inc at Piper Sandler Healthcare ConferenceForecast -Previous - |
| Monday, February 5, 2024 | ||
| Time (UTC) 21:00 | Country US
| Event Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Release Q1 2024 Arrowhead Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Friday, March 15, 2024 | ||
| Time (UTC) 17:00 | Country US
| Event Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting Arrowhead Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 243.231 | 138.287 | 87.9921 | 168.796 | 16.1423 |
| Revenue | 243.231 | 138.287 | 87.9921 | 168.796 | 16.1423 |
| Total Operating Expense | 421.738 | 287.323 | 181.151 | 107.605 | 72.0786 |
| Selling/General/Admin. Expenses, Total | 130.095 | 80.08 | 51.6649 | 26.5563 | 19.1101 |
| Research & Development | 281.222 | 198.977 | 123.543 | 81.0487 | 52.9685 |
| Depreciation / Amortization | 10.421 | 8.266 | 5.943 | ||
| Unusual Expense (Income) | 0 | ||||
| Other Operating Expenses, Total | 0 | ||||
| Operating Income | -178.507 | -149.036 | -93.1588 | 61.1906 | -55.9362 |
| Interest Income (Expense), Net Non-Operating | 5.033 | 6.12 | 9.1905 | 6.95777 | 1.48066 |
| Gain (Loss) on Sale of Assets | |||||
| Other, Net | 0.765 | 2.07 | -0.58252 | 0 | 0.00749 |
| Net Income Before Taxes | -172.709 | -140.846 | -84.5508 | 68.1484 | -54.4481 |
| Net Income After Taxes | -176.494 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
| Minority Interest | 0.431 | ||||
| Net Income Before Extra. Items | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
| Net Income | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
| Income Available to Common Excl. Extra. Items | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
| Income Available to Common Incl. Extra. Items | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
| Diluted Net Income | -176.063 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
| Diluted Weighted Average Shares | 105.426 | 103.745 | 100.722 | 98.6078 | 83.6385 |
| Diluted EPS Excluding Extraordinary Items | -1.67001 | -1.35764 | -0.83947 | 0.68935 | -0.65102 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -1.67001 | -1.35764 | -0.83947 | 0.68935 | -0.65102 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 15.825 | 146.267 | 62.546 | 31.575 | 32.412 |
| Revenue | 15.825 | 146.267 | 62.546 | 31.575 | 32.412 |
| Total Operating Expense | 118.528 | 98.102 | 104.68 | 115.405 | 105.321 |
| Selling/General/Admin. Expenses, Total | 26.69 | 25.159 | 22.651 | 31.624 | 32.738 |
| Research & Development | 88.563 | 70.273 | 79.34 | 81.121 | 69.98 |
| Depreciation / Amortization | 3.275 | 2.67 | 2.689 | 2.66 | 2.603 |
| Operating Income | -102.703 | 48.165 | -42.134 | -83.83 | -72.909 |
| Interest Income (Expense), Net Non-Operating | -0.986 | -0.497 | -0.167 | 1.583 | 1.24 |
| Other, Net | 0.306 | 0.008 | 0.507 | 0.09 | -0.377 |
| Net Income Before Taxes | -103.383 | 47.676 | -41.794 | -82.157 | -72.046 |
| Net Income After Taxes | -104.125 | 47.676 | -41.811 | -85.942 | -72.046 |
| Net Income Before Extra. Items | -102.946 | 48.675 | -41.325 | -85.511 | -72.046 |
| Net Income | -102.946 | 48.675 | -41.325 | -85.511 | -72.046 |
| Income Available to Common Excl. Extra. Items | -102.946 | 48.675 | -41.325 | -85.511 | -72.046 |
| Income Available to Common Incl. Extra. Items | -102.946 | 48.675 | -41.325 | -85.511 | -72.046 |
| Diluted Net Income | -102.946 | 48.675 | -41.325 | -85.511 | -72.046 |
| Diluted Weighted Average Shares | 107.004 | 108.143 | 106.039 | 105.885 | 105.753 |
| Diluted EPS Excluding Extraordinary Items | -0.96208 | 0.4501 | -0.38972 | -0.80758 | -0.68127 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.96208 | 0.4501 | -0.38972 | -0.80758 | -0.68127 |
| Minority Interest | 1.179 | 0.999 | 0.486 | 0.431 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 405.299 | 384.597 | 322.37 | 265.247 | 78.7686 |
| Cash and Short Term Investments | 376.396 | 367.789 | 315.492 | 258.704 | 76.5334 |
| Cash & Equivalents | 108.005 | 184.434 | 143.583 | 221.804 | 30.1332 |
| Short Term Investments | 268.391 | 183.355 | 171.909 | 36.8999 | 46.4002 |
| Total Receivables, Net | 1.41 | 10.255 | 0.84567 | 0.66136 | 0.32738 |
| Accounts Receivable - Trade, Net | 1.41 | 10.255 | 0.84567 | 0.66136 | 0.32738 |
| Prepaid Expenses | 7.289 | 4.362 | 4.2509 | 3.318 | 1.26772 |
| Other Current Assets, Total | 20.204 | 2.191 | 1.78169 | 2.56344 | 0.64012 |
| Total Assets | 691.939 | 710.148 | 522.504 | 349.845 | 111.61 |
| Property/Plant/Equipment, Total - Net | 168.588 | 66.021 | 47.0179 | 23.2149 | 13.9354 |
| Property/Plant/Equipment, Total - Gross | 200.142 | 88.885 | 63.3224 | 35.2966 | 23.7408 |
| Accumulated Depreciation, Total | -31.554 | -22.864 | -16.3044 | -12.0816 | -9.80536 |
| Intangibles, Net | 11.962 | 13.663 | 15.3631 | 17.0636 | 18.764 |
| Other Long Term Assets, Total | 0.218 | 0.272 | 0.26536 | 0.14415 | 0.14192 |
| Total Current Liabilities | 138.85 | 146.536 | 40.6814 | 97.0707 | 12.365 |
| Accounts Payable | 2.868 | 9.457 | 6.82891 | 7.64992 | 2.8061 |
| Accrued Expenses | 61.883 | 26.024 | 14.5442 | 11.4606 | 8.98069 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.22382 | |||
| Other Current Liabilities, Total | 74.099 | 111.055 | 19.3083 | 77.9601 | 0.35434 |
| Total Liabilities | 293.419 | 301.326 | 60.7246 | 105.254 | 15.8138 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 2.1012 |
| Long Term Debt | 0 | 2.1012 | |||
| Capital Lease Obligations | |||||
| Minority Interest | 19.819 | 0 | -0.55519 | -0.55519 | |
| Other Liabilities, Total | 134.75 | 154.79 | 20.0432 | 8.73851 | 1.9028 |
| Total Equity | 398.52 | 408.822 | 461.779 | 244.591 | 95.7962 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.198 | 0.197 | 0.19475 | 0.18788 | 0.18088 |
| Additional Paid-In Capital | 1219.21 | 1053.39 | 965.41 | 664.086 | 582.903 |
| Retained Earnings (Accumulated Deficit) | -820.755 | -644.692 | -503.844 | -419.291 | -487.266 |
| Other Equity, Total | -0.136 | -0.069 | 0.01843 | -0.39162 | -0.02156 |
| Total Liabilities & Shareholders’ Equity | 691.939 | 710.148 | 522.504 | 349.845 | 111.61 |
| Total Common Shares Outstanding | 105.96 | 104.327 | 102.376 | 95.5063 | 88.5053 |
| Total Preferred Shares Outstanding | |||||
| Long Term Investments | 105.872 | 245.595 | 137.487 | 44.176 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 470.165 | 574.81 | 574.999 | 405.299 | 432.388 |
| Cash and Short Term Investments | 444.403 | 481.005 | 501.831 | 376.396 | 416.496 |
| Cash & Equivalents | 98.034 | 134.959 | 202.249 | 108.005 | 139.439 |
| Short Term Investments | 346.369 | 346.046 | 299.582 | 268.391 | 277.057 |
| Total Receivables, Net | 1.247 | 69.434 | 39.568 | 1.41 | 0.239 |
| Accounts Receivable - Trade, Net | 1.247 | 69.434 | 39.568 | 1.41 | 0.239 |
| Prepaid Expenses | 10.053 | 9.935 | 8.412 | 7.289 | 6.761 |
| Other Current Assets, Total | 14.462 | 14.436 | 25.188 | 20.204 | 8.892 |
| Total Assets | 795.856 | 891.308 | 891.489 | 691.939 | 751.782 |
| Property/Plant/Equipment, Total - Net | 272.036 | 226.342 | 188.969 | 168.588 | 140.812 |
| Property/Plant/Equipment, Total - Gross | 310.956 | 262.414 | 222.804 | 200.142 | 170.147 |
| Accumulated Depreciation, Total | -38.92 | -36.072 | -33.835 | -31.554 | -29.335 |
| Intangibles, Net | 10.687 | 11.112 | 11.537 | 11.962 | 12.387 |
| Long Term Investments | 42.758 | 78.834 | 115.774 | 105.872 | 165.92 |
| Other Long Term Assets, Total | 0.21 | 0.21 | 0.21 | 0.218 | 0.275 |
| Total Current Liabilities | 70.227 | 87.151 | 122.009 | 138.85 | 128.212 |
| Accounts Payable | 7.874 | 9.556 | 0.796 | 2.868 | 5.894 |
| Accrued Expenses | 45.448 | 47.756 | 54.932 | 61.883 | 38.03 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 16.905 | 29.839 | 66.281 | 74.099 | 84.288 |
| Total Liabilities | 431.026 | 444.536 | 514.45 | 293.419 | 297.855 |
| Total Long Term Debt | 263.064 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 80.58 | 339.051 | 373.108 | 134.75 | 149.393 |
| Total Equity | 364.83 | 446.772 | 377.039 | 398.52 | 453.927 |
| Common Stock | 0.199 | 0.199 | 0.199 | 0.198 | 0.198 |
| Additional Paid-In Capital | 1281.39 | 1260.31 | 1239.18 | 1219.21 | 1189.11 |
| Retained Earnings (Accumulated Deficit) | -916.351 | -813.405 | -862.08 | -820.755 | -735.244 |
| Other Equity, Total | -0.411 | -0.332 | -0.258 | -0.136 | -0.14 |
| Total Liabilities & Shareholders’ Equity | 795.856 | 891.308 | 891.489 | 691.939 | 751.782 |
| Total Common Shares Outstanding | 107.102 | 106.869 | 106.14 | 105.96 | 105.795 |
| Minority Interest | 17.155 | 18.334 | 19.333 | 19.819 | 20.25 |
| Long Term Debt | 263.064 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -176.494 | -140.848 | -84.5532 | 67.9749 | -54.4505 |
| Cash From Operating Activities | -136.131 | 171.224 | -95.3916 | 173.035 | -47.2234 |
| Cash From Operating Activities | 10.421 | 8.267 | 5.94226 | 4.43914 | 4.69928 |
| Non-Cash Items | 128.235 | 76.939 | 43.9083 | 13.4624 | 8.40554 |
| Cash Taxes Paid | 0.002 | 0.002 | -0.10344 | 0.3024 | 0.0024 |
| Cash Interest Paid | 0 | 0 | 0 | 0.02744 | 0.17338 |
| Changes in Working Capital | -98.293 | 226.866 | -60.6889 | 87.1585 | -5.87776 |
| Cash From Investing Activities | -5.417 | -141.678 | -240.778 | -47.746 | -7.43496 |
| Capital Expenditures | -52.777 | -23.567 | -11.9517 | -12.0012 | -1.42125 |
| Other Investing Cash Flow Items, Total | 47.36 | -118.111 | -228.826 | -35.7448 | -6.01371 |
| Cash From Financing Activities | 65.186 | 11.305 | 257.948 | 66.382 | 59.953 |
| Financing Cash Flow Items | 60 | 0 | 0 | -0.05467 | |
| Issuance (Retirement) of Stock, Net | 5.186 | 11.305 | 257.948 | 68.7971 | 60.2162 |
| Issuance (Retirement) of Debt, Net | 0 | -2.41515 | -0.20851 | ||
| Net Change in Cash | -76.429 | 40.851 | -78.2215 | 191.671 | 5.29465 |
| Foreign Exchange Effects | -0.067 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 5.865 | -41.811 | -176.494 | -90.552 | -18.506 |
| Cash From Operating Activities | -107.187 | -75.516 | -136.131 | -67.464 | 1.383 |
| Cash From Operating Activities | 5.358 | 2.689 | 10.421 | 7.761 | 5.167 |
| Non-Cash Items | 47.826 | 22.929 | 128.235 | 99.465 | 62.789 |
| Changes in Working Capital | -166.236 | -59.323 | -98.293 | -84.138 | -48.067 |
| Cash From Investing Activities | -116.759 | -80.694 | -5.417 | -41.862 | -103.14 |
| Capital Expenditures | -66.225 | -38.911 | -52.777 | -20.066 | -10.53 |
| Other Investing Cash Flow Items, Total | -50.534 | -41.783 | 47.36 | -21.796 | -92.61 |
| Cash From Financing Activities | 251.096 | 250.576 | 65.186 | 64.331 | 3.731 |
| Issuance (Retirement) of Stock, Net | 1.096 | 0.576 | 5.186 | 4.331 | 3.731 |
| Net Change in Cash | 26.954 | 94.244 | -76.429 | -44.995 | -98.026 |
| Cash Taxes Paid | 0 | 0 | |||
| Cash Interest Paid | 0 | 0 | |||
| Financing Cash Flow Items | 250 | 250 | 60 | 60 | |
| Foreign Exchange Effects | -0.196 | -0.122 | -0.067 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 10.781 | 11556457 | -19535 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.2147 | 10949457 | 119024 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.138 | 5507571 | -395197 | 2023-06-30 | LOW |
| Anzalone (Christopher Richard) | Individual Investor | 3.4482 | 3696176 | -24338 | 2023-10-25 | MED |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.5373 | 2719819 | 1346572 | 2023-06-30 | LOW |
| Invesco Advisers, Inc. | Investment Advisor | 2.0135 | 2158340 | 48390 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0086 | 2153050 | 74523 | 2023-06-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 1.7002 | 1822537 | -51558 | 2023-06-30 | LOW |
| Rokos Capital Management LLP | Hedge Fund | 1.5635 | 1675921 | 0 | 2023-06-30 | HIGH |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.3854 | 1485073 | 311900 | 2022-12-31 | LOW |
| Credit Suisse Funds AG | Investment Advisor/Hedge Fund | 1.1534 | 1236323 | 3778 | 2023-06-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 1.0824 | 1160213 | -7150 | 2023-06-30 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 1.0682 | 1145059 | -12516 | 2023-06-30 | LOW |
| First Manhattan Co. LLC | Investment Advisor | 1.0254 | 1099154 | 73500 | 2023-06-30 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.8692 | 931677 | -6908 | 2023-06-30 | LOW |
| Avidity Partners Management LP | Hedge Fund | 0.8629 | 925000 | -816300 | 2023-06-30 | HIGH |
| Aquilo Capital Management, LLC | Investment Advisor/Hedge Fund | 0.8009 | 858474 | -160000 | 2023-06-30 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.7677 | 822929 | 822929 | 2023-09-30 | LOW |
| Western Financial Corporation | Investment Advisor | 0.7652 | 820239 | -70 | 2023-09-30 | LOW |
| Commodore Capital LP | Hedge Fund | 0.5691 | 610000 | 35000 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Arrowhead Pharma Company profile
Arrowhead Pharma| Industry: | Bio Therapeutic Drugs |
177 E Colorado Blvd
Suite 700
PASADENA
CALIFORNIA 91105
US
Income Statement
- Annual
- Quarterly
News
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023
XAU/USD Latest: Gold advances as weaker data weighs on US yields
Gold moves higher as softer economic data weighs on US yields and the dollar
13:43, 17 November 2023
Crude prices extend tumble as demand fears loom ahead of next OPEC+ meeting
Crude has extended its sell-off as demand risks loom ahead of OPEC+’s meeting on November 26. We look at the drivers of oil prices and the key technical levels of WTI Crude.
13:07, 17 November 2023
AUD/USD Retests Key Resistance Zone
The US dollar weakened notably following the latest CPI data, showing a larger-than-expected dip to 3.2% in October. This decline, the first in four months, sparked a surge in AUD/USD on Tuesday, pushing prices back into a crucial resistance zone established since August (see daily candle chart below).
10:24, 17 November 2023
Strategy Smarts Part 2: Trading Trend Days
Welcome to our four-part Strategy Smarts series designed to give you some practical trading templates which build on the concepts outlined in our Day Traders Toolbox and Power Patterns series. Today’s piece centres around Trend Days; what they are, how to spot them early and most importantly, how to trade them consistently.
10:18, 15 November 2023
Apple Regain Bullish Momentum
Apple's share price has rallied since the release of their recent financial results on 2nd November, despite certain concerns over growth in China.
10:17, 14 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com